RCSB PDB - 4A7A: Crystal structure of human monoamine oxidase B (MAO B) in complex with rosiglitazone (original) (raw)
Molecular Insights Into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs
[Binda, C.](/search?q=citation.rcsb%5Fauthors:Binda, C.), [Aldeco, M.](/search?q=citation.rcsb%5Fauthors:Aldeco, M.), [Geldenhuys, W.J.](/search?q=citation.rcsb%5Fauthors:Geldenhuys, W.J.), [Tortorici, M.](/search?q=citation.rcsb%5Fauthors:Tortorici, M.), [Mattevi, A.](/search?q=citation.rcsb%5Fauthors:Mattevi, A.), [Edmondson, D.E.](/search?q=citation.rcsb%5Fauthors:Edmondson, D.E.)
(2012) ACS Med Chem Lett 3: 39-42
PubMed Abstract:
The widely employed anti-diabetic drug pioglitazone (Actos) is shown to be a specific and reversible inhibitor of human monoamine oxidase B (MAO B). The crystal structure of the enzyme-inhibitor complex shows the R-enantiomer is bound with the thiazolidinedione ring near the flavin. The molecule occupies both substrate and entrance cavities of the active site establishing non-covalent interactions with the surrounding amino acids. These binding properties differentiate pioglitazone from the clinically used MAO inhibitors, which act through covalent inhibition mechanisms and do not exhibit a high degree of MAO A versus B selectivity. Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson's patients. They also provide new insights for the development of reversible isoenzyme-specific MAO inhibitors.
Organizational Affiliation:
Department of Genetics and Microbiology, University of Pavia, 27100 Pavia, Italy.